Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
246.44
+2.13 (+0.87%)
Streaming Delayed Price
Updated: 10:42 AM EDT, Jul 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
↗
July 02, 2026
The stock has soared more than 220% in three years.
Via
The Motley Fool
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 26, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Stocks to Buy and Hold for a Decade
↗
June 16, 2026
All three could become highly prominent biotech companies within 10 years.
Via
The Motley Fool
Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge
↗
May 04, 2026
Via
Chartmill
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
June 15, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
↗
June 06, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive...
Via
MarketBeat
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
June 04, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 03, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
↗
May 24, 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
↗
May 12, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive...
Via
MarketBeat
3 Stocks Poised to Disrupt the Healthcare Market by 2030
↗
May 08, 2026
The old healthcare model is breaking down.
Via
The Motley Fool
Topics
Artificial Intelligence
Axsome Therapeutics Recognizes Mental Health Month
May 07, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Overlooked Stocks Set to Soar in 2026
↗
May 05, 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Via
The Motley Fool
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
↗
May 04, 2026
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Via
The Motley Fool
Axsome (AXSM) Q1 2026 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome (AXSM) Q2 2025 Earnings Transcript
↗
May 04, 2026
Axsome (AXSM) Q2 2025 Earnings Transcript
Via
The Motley Fool
Axsome (AXSM) Q1 2025 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 04, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Axsome Therapeutics Stock Jumped Over 20% in April
↗
May 02, 2026
Axsome shares reached an all-time high last month, and there might be more to come.
Via
The Motley Fool
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Is This Healthcare Stock a Millionaire Maker?
↗
April 08, 2026
If it can establish itself as a leading biotech in the future, it might be.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
April 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
↗
March 25, 2026
The next 10 months might be challenging for this biotech.
Via
The Motley Fool
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
↗
March 18, 2026
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
